StockData
Elutia Inc. logo

Elutia Inc. (ELUT) company profile

ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/307% below fair value
$0.85+0.03 (+3.77%)

Close on Nov 17, 2026Market cap $37.82MP/E –Yield –

About Elutia

Biological Products, (No Diagnostic Substances), SIC 2836

Elutia Inc. develops and commercializes proprietary biologic matrix and drug-eluting biomatrix products designed for surgical reconstruction, soft tissue repair, and cardiovascular applications. Operating through reporting segments including Women’s Health and Cardiovascular, the company provides products such as SimpliDerm, a human acellular dermal matrix for soft tissue repair, and cardiovascular matrices including ProxiCor, Tyke, and VasCure. Its customer base consists of healthcare facilities and hospitals, supplied via independent sales agents, alongside plastic, reconstructive, cardiovascular, and general surgeons who utilize these products to support tissue healing and reduce post-operative complications.

The company operates primarily within the United States, which generated all commercial product sales in 2025 following the cessation of international sales in May 2024. Elutia is headquartered in Gaithersburg, Maryland, where it leases approximately 26,598 square feet of production, laboratory, and administrative space to direct corporate activities and development. It also maintains a corporate office located in San Diego, California.

Summary of the business section of Elutia's latest annual report, written by StockData.

Company profile

Company

Legal name
Elutia Inc.
Headquarters
Silver Spring, MD
Address
12510 Prosperity Drive, Suite 370 20904
Phone
(240) 247-1143
Website
elutia.com
Employees
26, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
ELUT
Former tickers
AZYO until Sep 7, 2023
Exchange
Nasdaq
IPO date
Oct 8, 2020
Shares outstanding
44M, Aug 10, 2026
Public float
$65.09M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1708527
CUSIP
05479K106
ISIN
US05479K1060
FIGI
BBG00BRBB838
Share class FIGI
BBG00BRBB847
EIN
47-4790334

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
C. Randal MillsPRESIDENT AND CEO, Director474,113
Matthew FergusonCHIEF FINANCIAL OFFICER494,389
Michelle LeRoux WilliamsCHIEF SCIENTIFIC OFFICER130,552
David ColpmanDirector31,098
Guido J. NeelsDirector125,000
Kevin RakinDirector5,225,098
Brigid MakesDirector27,000
Matt ZugaDirector–
Maybelle JordanDirector–
HighCape Capital, L.P.Director9,520,232

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.34M-$1.21M$717.87K$69–
FY2024$4.54M$5.09M$1.70M$173–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryIncentive payOtherTotalvs. prior year
C. Randal Mills
President and Chief Executive Officer
$600.00K$738.00K$6.28K$1.34M-70%
Matthew Ferguson
Chief Financial Officer
$385.00K$355.16K$6.86K$747.03K-59%
Michelle Williams
Chief Scientific Officer
$355.00K$327.49K$6.21K$688.70K-57%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 8, 2020
Offer price
$17.00
Securities offered
2,941,176
Gross proceeds
$50.00M
Exchange
Nasdaq
First trading day
Oct 8, 2020
First-day close
$14.50-14.7%
Lock-up ends (est.)
Apr 6, 2021

“​ • The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 26 employees, and 25 employees were employed full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?